Clinical trial
A Phase I Dose-Escalation Study of BMS-641988 in Patients With…
NCT00326586 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00326586 |
|---|---|
| Title | A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer |
| Official title | A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | AR Antagonist (BMS-641988) |
| Enrollment | 54 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | May 17, 2006 |
| Last update posted | Jan 25, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: